Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [21] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [22] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [23] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [24] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [25] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [26] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093
  • [28] The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases
    Dong, Rongrong
    Ji, Jiali
    Liu, Hong
    He, Xuexin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 20 - 26
  • [29] Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
    Zhang, Jing
    Li, Jinying
    Zhu, Chenjing
    Song, Yanlin
    Xia, Fan
    Ma, Xuelei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3235 - 3244
  • [30] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
12345